Navigation Links
West Announces Third Quarter 2009 Results
Date:11/3/2009

As Reported Non-GAAP September 30, Brazil Tax September 30, 2009 Tax Benefits Amnesty 2009 ---- ------------ ------- ---- Operating profit $25.9 $- $(3.9) $22.0 Interest expense, net 3.5 - - 3.5 --- -- -- --- Income before income taxes 22.4 - (3.9) 18.5 Income tax expense 6.0 0.4 (2.2) 4.2 Equity in net income of affiliated companies 0.8 - - 0.8 --- -- -- --- Net income 17.2 (0.4) (1.7) 15.1 Less: net income attributable to noncontrolling interests - - - - -- -- -- -- Net income attributable to common shareholders $17.2 $(0.4) $(1.7) $15.1 ----- ----- ----- ----- Net income per diluted share attributable to common shareholders $0.50 $(0.01) $(0.04) $0.45 ----- ------ ------ ----- WEST PHARMACEUTICAL SERVICES NON-GAAP MEASURES (UNAUDITED) THREE MONTHS ENDED SEPTEMBER 30, 2008 (in millions, except per share data) As Reported Contract Non-GAAP September 30, settlement September 30, 2008 cos
'/>"/>
SOURCE West Pharmaceutical Services, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 1Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 2Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 3Jiangbo Pharmaceuticals to Present at Rodman 26 Renshaw Annual Global Investment Conference 13788 1Jiangbo Pharmaceuticals to Present at Rodman 26 Renshaw Annual Global Investment Conference 13788 2Jiangbo Pharmaceuticals to Present at Rodman 26 Renshaw Annual Global Investment Conference 13788 3September 2009 is Atrial Fibrillation Month 55975 1September 2009 is Atrial Fibrillation Month 55975 2